Skip to content

COPD stage-dependent prevalence of PAD with special consideration of inflammation and exacerbation rate

COPD stage-dependent prevalence of PAD with special consideration of inflammation and exacerbation rate

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00023759
Enrollment
200
Registered
2020-12-16
Start date
2021-01-11
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I70.2 J44.9

Interventions

Group 1: The study is designed as a diagnostic study. Patients will be evaluated for the study as part of the control of the known COPD. There is to be done an anamnesis, questionnaire, clinical exami

Sponsors

Praxis RechPneumologie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient capable of giving consent Diagnosed with COPD

Exclusion criteria

Exclusion criteria: Other lung diseases Serious comorbidities Incapable of giving consent / persons under 18 years of age. pregnancy Tumor therapy

Design outcomes

Primary

MeasureTime frame
The anamnesis is followed by the ABI (Ankle Brachial Index) measurement, lung function test, determination of the walking distance ( 6 minutes’ walk distance) and measurement of hsCRP in serum The study is designed for a period of 6-12 months or a case number of 200 patients. The primary endpoint is the answer to the question of whether a PAD is present and the assignment to a stage of the PAD

Secondary

MeasureTime frame
How high is the unreported number of PAD in COPD patients. Which screening methods are useful in the routine for patients with COPD with regard to the question of the presence of PAD?

Countries

Germany

Contacts

Public ContactAlexander Rech

Praxis RechPneumologie

praxisrech@yahoo.de00495311218685

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026